CIPROFIBRATE IN TREATMENT OF TYPE-2A HYPE RLIPOPROTEINEMIA IN POSTMENOPAUSAL WOMEN

Efficacy, safety, and tolerability of ciprofibrate (100 mg/day) were s tudied in 14 postmenopausal women. After 3 months of treatment low den sity lipoprotein cholesterol, total cholesterol, triglycerides, and to tal/low density cholesterol ratio decreased by 28,4%, 22,2%, 38,5%, an d 35,1%, respectively, while high density lipoprotein cholesterol incr eased by 16,8%. There were no elevations (above 2 upper limits of norm al) of creatine phosphokinase, alanine and aspartate aminotransferase while activity of alkaline phosphatase decreased by 41,6%. One patient stopped taking the drug because of individual intolerance. Thus in po stmenopausal women with type 2a hyperlipidemia ciprofibrate appeared t o be effective and safe lipid lowering drug.